RxDoctor Payments Data

David Hagaman, MD

Allergy · Nashville, TNNPI 1235221656

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $352,282 of the $446,241 with a category attached, or 78.9%. 11 manufacturers reported payments, led by Sanofi at 56.2% of the total. Reporting peaked in 2019 at $126,578 and has fallen 72.0% since, to $35,414 in 2025.

$446,241in general payments, 2019–2025

Across 460 payments — averaging $970.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$251K
  • Regeneron Healthcare Solutions, Inc.$180K
  • GSK$11K
  • AstraZeneca$2K
  • Jazz Pharmaceuticals Inc.$927
  • Takeda Pharmaceuticals U.S.A., Inc.$332
  • plus $948 from 5 others

What the payments were for

  • Consulting fees$6330%
  • Speaking & faculty fees$352,28279%
  • Travel & lodging$80,69918%
  • Food & beverage$12,6033%
  • Education$230%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy providers in Tennesseeto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$353,431
Medicare patients
379
Services billed
13,927

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab41$151,834
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5025$134,330
Dupixent PenDupilumab31$120,152
Trelegy ElliptaFluticasone/Umeclidin/Vilanter95$73,460
Spiriva RespimatTiotropium Bromide116$70,680
Advair HfaFluticasone Propion/Salmeterol124$53,709
Breztri AerosphereBudesonide/Glycopyr/Formoterol79$52,583
Breo ElliptaFluticasone/Vilanterol85$46,145
SymbicortBudesonide/Formoterol Fumarate117$35,716
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate137$29,166
DuleraMometasone/Formoterol46$18,484
BreynaBudesonide/Formoterol Fumarate85$15,554
Azelastine Hcl483$15,185
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$7,313
Epinephrine22$6,150

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$332$134,33025 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$11,266$131,088213 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,716$88,300196 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy providers in Tennesseeon file to place this against a meaningful peer group, so we don't.

Other allergy in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →